Calidi Biotherapeutics, Inc. (CLDI) Stock Analysis

Company Overview

Calidi Biotherapeutics, Inc. operates as a clinical stage immuno-oncology company focused on developing allogeneic stem cell-based and enveloped virus platforms designed to potentiate and deliver oncolytic viruses within the United States. The firm functions within the healthcare sector, specifically the biotechnology industry, which implies a reliance on substantial research and development expenditures to advance product candidates through various stages of clinical evaluation. The company currently maintains a market capitalization of $2.57M and employs a workforce of 28 individuals, with no reported revenue figures available for the trailing twelve months. These valuation and scale metrics indicate that the entity is an early-stage development company where equity value is derived primarily from the potential of its clinical pipeline rather than current cash flows or sales revenue.

Financial Health

For the trailing twelve months, the company reported revenue of N/A, a net income of $-25,620,000, and an EBITDA of $-19,312,000, highlighting a significant structural gap between revenue generation and profitability. The absence of revenue combined with a net loss of $25.62 million reveals a cost structure heavily weighted toward operational expenses and research activities typical of pre-revenue biotechnology firms. Free cash flow stands at $-13,038,500, indicating that the company is burning cash rapidly and lacks the immediate financial flexibility to fund operations without external capital infusion or dilution. All three margins—gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%—reflect the standard financial profile of a development-stage company that has not yet achieved commercial product sales. The company holds $10.38M in cash against $3.31M in debt, resulting in a debt-to-equity ratio of 45.96, which suggests a leveraged balance sheet relative to its equity base despite the nominal debt amount. The current ratio of 2.12 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate buffer for liquidity needs in the near term. Return on Equity is listed as N/A due to the lack of net income, while the Return on Assets metric stands at -119.6%, revealing that the company's assets are generating negative returns on a current basis.

Valuation Assessment

The trailing twelve-month P/E ratio is 0.75, while the forward P/E is -0.30, a disparity that implies the market expects earnings to remain negative in the near future before potentially turning positive. The price-to-book ratio is 0.28, indicating that the stock trades at a significant discount to its book value, which is common for speculative biotechnology assets with unproven commercial potential. Since revenue is N/A, the price-to-sales ratio is also N/A, and the EV/EBITDA stands at 0.25, suggesting that traditional earnings-based valuation models are less applicable than asset or pipeline-based assessments for this specific entity. The stock has a 52-week high of $19.20 and a 52-week low of $0.26, placing the current valuation context within a highly volatile trading range that spans nearly two orders of magnitude. The beta value is 1.11, meaning the stock exhibits price volatility that is slightly higher than the broader market, reflecting the heightened risk premium associated with clinical-stage biotechnology investments.

Growth & Income

Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, preventing a direct comparison of growth rates between the two metrics due to the lack of historical financial data in the provided records. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available earnings are theoretically retained for reinvestment rather than distributed to shareholders. Since the company is not a dividend payer, it operates on a model where capital is reinvested into growth initiatives such as clinical trials and platform development rather than providing income through distributions. The overall growth and income profile is currently defined by capital appreciation potential rather than income generation or historical revenue expansion metrics.